Seattle BioMed Starts Malaria Trial
Luke Timmerman5/13/10
Seattle Biomedical Research Institute said today it has officially started the first human clinical trial of its malaria vaccine candidate. The trial will assess the safety of a genetically engineered version of the malaria parasite. I wrote about this trial in depth back in March based on an interview with Seattle BioMed’s lead researcher on the program, Stefan Kappe. If the vaccine candidate passes this initial safety test, the Seattle-based nonprofit said it plans to start a mid-stage trial, in late 2010 or early 2011, to examine the vaccine’s effectiveness.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.
